News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Elite Pharmaceuticals, Inc. (ELI) Holds Clinical Guidance Meeting With The FDA On Its Abuse Deterrent Pain Program


10/27/2006 11:06:03 AM

NORTHVALE, N.J.--(BUSINESS WIRE)--Elite Pharmaceuticals, Inc. (AMEX: ELI) met with the U.S. Food and Drug Administration (FDA) for a Type C clinical guidance meeting regarding ELI-216, the Company’s abuse deterrent oxycodone hydrochloride product. The purpose of the meeting was to review the complete abuse deterrent clinical program. The FDA provided guidance and comments on the New Drug Application (NDA) 505(b)2 program proposed by the Company that are helpful in understanding the steps needed to complete the entire developmental program for this product. As a result of meeting with the FDA, the Company expects to continue with the development program and timetable outlined as previously disclosed.

>>> Discuss This Story


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES